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Abstract 
Purpose of Review: In this review we discuss the role of perivascular adipose tissue 
(PVAT) in the modulation of vascular contractility and arterial pressure, focusing on 
the role of the renin-angiotensin-aldosterone system and oxidative 
stress/inflammation.  
Recent Findings: PVAT possesses an relevant endocrine-paracrine activity, which 
may be altered in several pathophysiological and clinical conditions. During the last 
two decades it has been shown PVAT may modulate vascular reactivity. It has also 
been previously demonstrated that inflammation in adipose tissue may be implicated 
in vascular dysfunction. In particular, adipocytes secrete a number of adipokines with 
various functions, as well as several vasoactive factors, together with components of 
the renin-angiotensin system which may act at local or at systemic level. It has been 
shown that the anticontractile effect of PVAT is lost in obesity, probably as a 
consequence of the development of adipocyte hypertrophy, inflammation, and 
oxidative stress.  
Summary: Adipose tissue dysfunction is interrelated with inflammation and 
oxidative stress, thus contributing to endothelial dysfunction observed in several 
pathological and clinical conditions such as obesity and hypertension. Decreased local 
adiponectin level, macrophage recruitment and infiltration, and activation of renin-
angiotensin-aldosterone system could play an important role in this regards. 
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1. Potential role of PVAT in the modulation of arterial pressure 
  
The majority of blood vessels are surrounded by variable amounts of PVAT. For 
many years PVAT was routinely removed from arteries during in vitro studies, in 
order to simplify the experiments on isolated blood vessels. However, due to the 
increasing evidence of the role of the adipose tissue as an endocrine organ (1) and of 
the close proximity of PVAT to a vast network of blood vessels, investigators have 
begun to study the effects of PVAT (Table 1).  
In 1991 Soltis and Cassis were the first to test the hypothesis that PVAT might be 
important for vascular regulation (2). They demonstrated the presence of a a 
diminished response to noradrenaline in intact arteries compared with vessels having 
PVAT removed in isolated aortic ring preparations from rats. They attributed this 
effect to the dense sympathetic innervation in PVAT (2). Ten years later the interest 
in PVAT was renewed by Lohn et al (3). They demonstrated that the vasocontractile 
response with angiotensin II (Ang II), serotonin and phenylephrine was 95%, 80% 
and 30% lower respectively after removal of PVAT (3). Furthermore this effect was 
independent of nitric oxide (NO) formation and appeared to be mediated by a 
substance released from intact aortic rings surrounded with fat into the organ bath 
since transferral of bath solution from vessels with fat or cultured rat adipocytes to 
vessels without fat resulted in rapid relaxation of pre-contracted arteries. The factor 
involved was considered to be more likely a protein than a lipid, as it was not 
adsorbed by essentially fatty acid-free serum albumin and it was inactivated by 
heating. Therefore, the Authors  concluded that “adventitium derived relaxing factor” 
(ADRF) was released by PVAT (3).  
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ADRF release was shown to depend on extracellular calcium and can be modulated 
by changes in calcium concentration in the plasma in vivo (4). Furthermore, ADRF 
effect is regulated by intracellular tyrosine kinase, protein kinase A and voltage 
dependent smooth muscle potassium channel but not by NO, cytochrome P450 
pathways or prostaglandins (4). We now know that the relaxing factor is released 
from the adipose tissue and not from the tunica adventitia (5) and therefore we can 
use the term PVAT-derived relaxing factor (PDRF). Subsequent studies confirmed the 
role of PVAT as an inhibitor of arterial contraction in internal thoracic arteries (6) and 
in human internal mammary arteries (7). The mechanism of the vasodilatory capacity 
of PVAT varies depending on anatomical location and animal species. In rat aorta, 
PDRF appears to cause vasorelaxation by opening ATP-dependent K+ (KATP) 
channels in vascular smooth muscle cell (4), whilst in rat mesenteric arteries, voltage 
dependent K+ channels (Kv) seem to be involved (8).  In a recent study Gao et al 
identified two different pathways for explaining the PVAT relaxation on rat aorta. 
They described an endothelium-dependent and endothelium independent mechanism, 
working through release of nitric oxide with calcium sensing K+ channels activation 
(KCa) (5) and hydrogen peroxide with soluble guanylate cyclase activation (5), 
respectively.  Several studies both in vitro and in vivo have confirmed the 
anticontractile property of PVAT but despite several candidates being proposed, the 
real identity of PDRF is partly unknown.  
 
Candidates for PDRF : 
Leptin: Leptin has been proposed as PDRF because of its direct vasodilator effect by 
release of nitric oxide with endothelium-dependent mechanism (9,10). However, 
leptin possesses also contractile effects by activation of the sympathetic nervous 
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system and several other effects such as increase in vasoconstrictor endothelin-1 (11) 
and in toxic reactive oxygen species (ROS) (12). Therefore, leptin may contribute to 
arterial pressure homeostasis and to the anticontractile effect of PVAT but its role as 
PDRF seems to be unlikely. 
Adiponectin: The PVAT has been shown to secrete other vasodilator products like 
hydrogen peroxide (13) and adiponectin (14,15). In particular adiponectin is a protein 
secreted exclusively by adipose tissue (16) and it has been reported to possess several 
protective properties against hypertension (17,18,19), atherosclerosis (20) and 
diabetes (21). Several studies have demonstrated that adiponectin acts as a vasodilator 
by activation of endothelial NO synthase (eNOS) and consequent increase of NO 
production (21). It has the ability to inhibit macrophage activation, to reduce 
proliferation of vascular smooth muscle cells, to improve insulin signalling pathways  
and to reduce ROS levels (22,23). Hypoadiponectinemia has been correlated to 
endothelial dysfunction (24), obesity (25), hypertension (18), atherosclerosis (19), 
type 2 diabetes (20) and myocardial infarction. In particular, it has been shown that in 
patients with coronary artery disease epicardial tissue expresses lower adiponectin 
levels (26). Recent studies have demonstrated adiponectin-mediated anticontractile 
properties of PVAT in human small arteries, which represent the main regulators of 
peripheral resistance and hence of blood pressure (27). In particular, in that study it 
has been demonstrated that the anticontractile function of PVAT disappears in healthy 
human arteries after blockade of adiponectin receptor 1 (27). Considering its 
beneficial and protective effects, adiponectin could be an important therapeutic target. 
Therefore adiponectin might represent a reliable candidate for the role of PDRF. 
Aside from vasodilator products, PVAT has been also reported to secrete 
vasoconstrictor peptides like endothelin and Ang II (28) (Figure 1).  
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Inflammatory cytokines: The adipokines group also includes proinflammatory 
cytokines (such as interleukin 6 [IL-6], tumor necrosis factor [TNF-α]) chemokines 
(like interleukin 8 [IL-8] and monocyte chemoattractant protein-1 [MCP-1]) growth 
factors (transforming growth factor-β [TGF-β]) and pro-thrombotic factors (eg, 
plasminogen activator inhibitor type 1 [PAI-1]. 
 There is a compelling evidence for an increased level of adipokines in inflammatory 
state, such as in obesity, and of a decreased cardiometabolic protective role of 
adiponectin. These obesity-related changes in adipose tissue are probably linked to the 
development of insulin resistance, type 2 diabetes mellitus, hypertension and, thus, 
metabolic syndrome (29-32).  
In addition to this emergent role of PVAT as modulator of arterial tone, in a recent 
study it has been suggested that PVAT may act also as a regulator of vein function. In 
particular PVAT is able to reduce contractile responses of the inferior vena cava to 
various agonists mediated by angiotensin (1-7) through activation of Kv channels (33). 
Therefore the PVAT may play a role as dual modulator of vascular tone.  
It is clear that adipose tissue and in particular PVAT is a secretory and endocrine 
organ which is involved in the regulation of vascular tone. PVAT might play an 
important role in the modulation of blood pressure, in the hemodynamic homeostasis 
and in other conditions associated to vascular dysfunction such as atherosclerosis, 
obesity and type 2 diabetes mellitus. This suggests that a balance between adipose 
tissue-derived vasodilator and vasoconstrictor mediators might be extremely 
important for the maintenance of an appropriate vascular tone. 
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Table 1: Potential mechanisms involved in vascular-relaxation by PVAT 
 
 
 
 
Soltis et al 
(1991)2 
Aorta Rat Noradrenaline Vasodilatation Increased uptake of Noradrenaline with 
PVAT 
Lohn et al 
(2002)3 
Aorta Rat Phenylephrine 
Angiotensin II 
Serotonin 
Vasodilatation 1. Endothelium independent action 
2. Activation of ATP dependent K+ 
channels (KATP) 
Dubrovska 
et al 
(2003)4 
Aorta Rat Phenylephrine and 
Serotonin 
Vasodilatation 1. Ca2+dependent 
2. Tyrosine & protein kinase A 
dependent intracellular signalling 
pathways 
3.Indipendent of perivascular nerves 
Archer SL 
et al 
(2003)7 
Internal 
mammary 
arteries 
Human Bradykinin, 
Acetylcholine & 
11,12-
epoxyeicosatrienoic 
acid 
Vasodilatation Activation of Smooth Muscle Cells large-
conductance Ca2+-activated K+ channels 
(BKCa). 
 
Verlohren 
et al 
(2004)8 
Mesenteric 
arteries 
Rat Phenylephrine 
Adrenaline 
Serotonin 
Vasodilatation 1. Endothelium independent action 
2. Activation of Voltage dependent K+ 
channels (Kv) 
Gao et al 
(2005)6 
Internal 
thoracic artery 
Human Phenylephrine 
U46619 
Vasodilatation Activation of Calcium sensing K+ channels 
(KCa) 
Galvez et 
al (2006)9 
Mesenteric 
arteries 
Rat Serotonin 
U46619 
Vasodilation Activation of Voltage dependent K+ 
channels (Kv) 
Gao et al 
(2007)5 
Aorta Rat Phenylephrine 
Serotonin 
Vasodilatation 1. Endothelium-dependent relaxation by 
Nitric oxide release & KCa activation 
2. Endothelium independent mechanism 
involving H2O2 & activation of soluble 
Guanylate Cyclase 
Malinowski 
et al 
(2007)34 
Internal 
thoracic artery 
Human Angiotensin II 
Serotonin 
Vasodilatation non-Nitric Oxide, non-prostacyclin 
dependant mechanism 
Greenstein 
et al 
(2009)27 
Subcutaneous 
gluteal biopsy  
small arteries & 
mesenteric 
arteries  
Human 
and rat 
Norepinephrine Vasodilatation Endothelium-dependent relaxation by 
adiponectin through an increase Nitric 
oxide bioavailability 
Lee RM et 
al 
(2009)35,36 
Mesenteric 
resistance 
arteries, Aorta 
Rat Phenylephrine, 
serotonin, 
Angiotensin II 
Vasodilation Endothelium-dependent relaxation by 
angiotensin 1-7 through Nitric Oxide, via 
activation  KCa  channels  
Lu C et al  
(2011)33 
Inferior vena 
cava 
Rat Phenylephrine, 
U46619 & 5- 
hydroxytryptamine 
Vasodilatation Endothelium-dependent relaxation by 
angiotensin 1-7 via the activation  Kv 
channels 
Study District Species Agonist Effect of PVAT 
on vascular 
tone 
Potential mechanism proposed 
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Figure 1: Hormones and other substances secreted by adipose tissue. Abbreviations: ASP, 
acylation stimulating protein; IL-6, interleukin 6; PAI-1, plasminogen activator inhibitor type 
1; TF, tissue factor; TGF-β, transforming growth factor β; TNFα, tumor necrosis factor α. 
Diagram modified from Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends in 
Endocrinology & Metabolism 2000; 11(8): 327-32. 
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2. The adipose tissue and the renin-angiotensin axis 
 
The renin-angiotensin system (RAS) is involved in systemic blood pressure regulation 
and in renal electrolyte homeostasis. Several studies have demonstrated the presence 
of local RAS activity in both white and brown perivascular adipose tissue (37). 
A number of animal studies have demonstrated the expression of most of the RAS 
system components in adipose tissue (38), however data from human tissues are 
relatively few (39)  (Figure 2). 
 
 
 
Figure 2: Perivascular adipose tissue and local Renin-Angiotensin System. From Cassis LA, Police 
SB, Yiannikouris F, Thatcher SE. Local adipose tissue renin-angiotensin system. Curr Hypertens Rep 
2008; 10(2): 93-98.(40) 
 
 
 
 
10 
 
Angiotensinogen (AGT) expression in adipose tissue was first identified in periaortic 
brown adipose tissue in 1987 (41). Subsequently, AGT secretion and AGT-mRNA 
were detected in rat and human adipose tissue depots, in adipocytes isolated from rat 
arterial vessels walls and mesentery (42), in primary cultured human adipocytes (35) 
and in differentiating human pre-adipocytes (43). Thus the AGT expression and 
secretion is considered a late marker of adipocyte differentiation (44). Various studies 
have demonstrated that AGT expression is higher in visceral compared to 
subcutaneous adipose tissue in rats (45) and humans (46). In addition, white adipose 
tissue is considered to be one of the major sources of angiotensinogen outside the 
liver (47). The AGT activation by free fatty acids and overfeeding provides a possible 
link between adipose-tissue RAS, obesity/insulin resistance and obesity/hypertension.  
 
Although renin activity has been detected in brown adipose tissue (48), Gàlvez-Prieto 
et al showed the absence of renin expression in mesenteric and aortic PVAT from 
male Wister Kyoto rats (38). Nevertheless, they confirmed the presence of the 
(pro)renin receptor which may act with a circulating enzyme to increase local 
synthesis of angiotensin I from AGT. The peroxisome proliferator activated receptors 
(PPARs), of which two isoforms (α and γ) have been identified in PVAT, have both 
been shown to positively regulate renin transcription (49). This receptor has been 
detected in subcutaneous and visceral human adipose tissue (50).  
 
Ang II is the major component of RAS with a variety of physiological actions 
including vasoconstriction, stimulation of aldosterone release from the adrenal gland, 
renal sodium and water reabsorption, increase of blood pressure, cell growth, 
inflammation process, vascular and cardiac remodelling, activation of the sympathetic 
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nervous system and ROS production (51). In the adipose tissue Ang II may play a role 
in adipocyte growth and differentiation, stimulating lipogenesis, pre-adipocytes 
recruitment and their differentiation in mature adipocytes (40). 
The exact role of Ang II in the differentiation and proliferation of human adipocytes 
remains controversial; it has been shown that preadipocytes from human adipose 
tissue express a functional renin angiotensin system (RAS) (52). Sharma hypothesized 
that Ang II may be able to inhibit the adipogenic differentiation of primary cultured 
preadipocytes in humans (53). Ang II levels in mesenteric adipose tissue are higher 
than in periaortic adipose tissue (38), demonstrating a regional different expression of 
the RAS. 
The effects of Ang II are mediated by two main membrane receptors: the angiotensin 
type 1 receptor (AT1R) and the angiotensin type 2 receptor (AT2R).  Matsushita et al. 
demonstrated that Ang II stimulated differentiation of adipocytes through AT1R and 
inhibited it through AT2R (54). The AT1R is responsible for most biological effects 
of Ang II, such as pressure, trophic and pro-inflammatory effects, whereas the AT2R 
antagonizes several AT1R-mediated effects. It has been demonstrated that Ang II 
through AT1R stimulates transcription factor expression, which may promote 
adipocytes differentiation and increase of triglycerides content in human adipocytes 
culture and in 3T3-L1 cells, thus leading to adipocyte hypertrophy (55). The crucial 
role of AT1R is confirmed by the demonstration that, in essential hypertensives 
patients, in adipocytes in culture and in a rat model of type 2 diabetes, AT1R 
antagonist is able to increase adiponectin concentrations and improve insulin 
sensitivity (56,57). In addition, it has been demonstrated that telmisartan, a selective 
AT1R-blocker, increases adiponectin level and reduces myocardial damage in 
infarcted Zucker diabetic fatty rats models (58). It has been already shown that plasma 
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adiponectin levels were significantly increased in patients with hypertension after 
treatment with telmisartan (59). A previous study had also shown that treatment with 
the AT1R antagonist, olmesartan, in Ang II-infused rats resulted in an increase of 
adiponectin level (60) 
Conversely, the binding between Ang II and its AT2R may determine tissue 
regeneration (25) and up-regulation of adiponectin production in neonatal rat 
ventricular myocytes (61) 
Although the role of Ang II on differentiation and proliferation of adipocytes is still 
controversial, Ang II -related effects on adipose tissue, with its trophic and pro-
inflammatory effects, could play an important role for vascular function and structure 
and could be implicated in hypertension-related obesity.  
 
3. Changes of the RAS-axis in obesity and hypertension: contribution of the 
tissue RAS of PVAT 
Abdominal obesity is an important risk factor for the development of arterial 
hypertension, insulin resistance and type 2 diabetes. Abdominal obesity is also 
associated with metabolic and morphological abnormalities including sodium 
retention, endothelial dysfunction, left ventricular hypertrophy, dyslipidemia, 
hyperinsulinemia, microalbuminuria, elevated markers of inflammation and oxidative 
stress (62).  
Increasing evidence suggests a link between renin-angiotensin-aldosterone system 
(RAAS) and other components of the metabolic syndrome, in particular abdominal 
obesity. A Japanese study has shown that oxidative stress, an important mechanism of 
metabolic dysregulation in obesity, is able to reduce mRNA-AGT levels in adipose 
tissue of obese and in hypertrophic murine adipocytes (63). Oxidative stress is closely 
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correlated to RAAS; Ang II is a potent inductor of reactive oxygen substances (ROS) 
and during obesity systemic and related adipose tissue Ang II levels are increased.  
In addition to Ang II, aldosterone is also an important mediator of RAAS effects. In 
obesity-related hypertension aldosterone levels are higher and they are associated with 
endothelial dysfunction (64) and inflammation (65). In a study of 2009, it has been 
shown that the blockade of mineralcorticoid-receptors improves adipocyte 
dysfunction and insulin resistance in a murine model of obesity (66). A recent review 
discusses the known interaction between adiponectin and aldosterone, demonstrating 
an inverse relationship (67). Several effects of aldosterone are mediated through 
pathways similar to those induced by Ang II. Furthermore, recent data demonstrate 
the presence of cross-talk between aldosterone and Ang II which modulates and 
stimulates the signalling transduction such as the Ang II effects on PVAT (68).  
 
The tissue RAS of PVAT may operate in combination or independently of circulating 
RAS. The precise function of RAS in perivascular adipose tissue is still controversial 
but may contribute to vascular tone, structural and functional alterations, especially in 
pathological conditions such as hypertension and obesity, amplifying the effect of 
systemic RAS. It has been hypothesized cross-talk between smooth muscle cells and 
endothelial cells which could explain at least in part the implication of tissue RAS in 
the perivascular adipose tissue on structural alterations of small resistance arteries. 
In view of the relevant role of the RAS system and PVAT on vascular function, it is 
interesting to understand the possible relationship between them. 
In 2006 Gàlvez and colleagues observed several changes in PVAT function and mass 
in spontaneously hypertensive rats (SHR) which could contribute to increased 
vascular resistance (9). In the SHR model, PVAT has a reduced anticontractile effect, 
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being the mass of mesenteric PVAT less than in control mice with smaller adipocytes 
and lower leptin content (9). Subsequently, Lee demonstrated that the changes on 
PVAT structure and function were observed also in Ang II-induced hypertension in 
adult male Wistar normotensives rats (35). In addition, it has been also shown that 
Ang II is able to mediate PVAT-associated increase of contractile response to 
perivascular neuronal excitation by EFS, possibly through superoxide production 
(69).  Recently the same author confirmed the reduced anticontractile function of 
PVAT in SHR (70) and this functional impairment could involve angiotensin (1-7) 
(70). In fact, angiotensin (1-7) blockade is able to inhibit the anticontractile effect of 
PVAT (36). Ang 1-7 has been also implicated on anticontractile function showed by 
PVAT on inferior vena cava (33).  
 
In a study of 2011, in a mouse model, we demonstrated that PVAT in small 
mesenteric arteries loses its anticontractile effect, after stimulation with two 
physiological stimuli of inflammation: aldosterone and hypoxia (71).  
In that study we demonstrated that the presence and activation of macrophages in 
adipose tissue was a key modulator of the increased in contractility in arteries with 
PVAT following induction of inflammation. Among multiple factors that may be 
involved in determining the vascular consequences of obesity and hypertension, we 
have shown a favorable effect of eplerenone in inducing a reduction of the 
inflammatory effects of both aldosterone and hypoxia (71). This property of 
mineralcorticoid-receptors blockers may be of potential therapeutic interest. In a 
recent study we demonstrated that also an ACE-inhibitor and an AT1R blocker have 
similar effects on anticontractile properties of the perivascular adipose tissue 
following hypoxia (72). In particular, we have shown that hypoxia induced a loss of 
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this anticontractile effect which could be completely prevented with captopril or 
telmisartan. Therefore our in-vitro induction of a hypoxic environment can simulate 
the loss of anticontractile perivascular adipose tissue function seen in vivo in obese 
patients, and this can be prevented using inhibitors of the renin–angiotensin cascade; 
RAS blockade may protect the vasculature and may reverse the effect of perivascular 
and systemic RAS. 
 
 
4 The role of oxidative stress and inflammation in PVAT function 
It is well known that vascular dysfunction is mediated by adipose tissue inflammation 
which could be contrasted by anti-inflammatory agents such as adiponectin. Recently 
a review from Huang Cao et al described the important role of PVAT on regulation of 
vascular tone underlining the importance of the functional integrity of PVAT, rather 
than the amount of PVAT itself, because it’s essential for the control of blood 
pressure and it’s protective against the development of hypertension and 
cardiovascular disease (73). In particular in lean conditions the PVAT is able to 
secrete several adipokines which act on endothelial cells through a nitric-oxide 
dependent mechanism and directly on small muscle cells to induce vasorelaxation of 
the vessel wall. Instead during obesity the secretory profile of PVAT change with a 
reduction of expression of vasorelaxing factors and an increase in vasoconstricting 
factors with cell infiltration leading to inflammatory state (73). The cause of the onset 
of inflammation remains still unknown although a recent hypothesis is related to 
hypoxia; in obesity, adipocytes become hypertrophic leading to inadequate perfusion 
and consequent local hypoxia. Hypoxia-inducible factor (HIF-1 α) alpha is a key 
mediator of hypoxia. Its levels are higher in adipose tissue of obese subjects and they 
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decrease after weight loss (74). HIF-1 α is a main hypoxia-inducible transcription 
factor responsible for increased inflammatory mediator production, like TNF-α and 
IL-6, and for reduced adiponectin level (75). Greenstein et al have shown that the 
application of TNF-α and IL-6 to PVAT around healthy blood vessels decreased the 
dilator effect of PVAT. Similarly, it has been shown that the induction of 
experimental hypoxia for 2.5 hours causes inflammation and loss of anticontractile 
function of PVAT. Both conditions could be reversed and the anticontractile property 
rescued by catalase and superoxide dismutase or cytokine antagonists (27). From 
these observations it is clear that PVAT loses its dilating effect after the increase of 
oxidative stress. 
In addition to hypoxia, there are also different HIF activators such as growth factors, 
cytokines and hormones. In particular, it has been demonstrated that in vascular 
smooth muscle cells, Ang II is a potent activator of HIF-1 α by mechanisms even 
different from hypoxia, involving also mitochondrial reactive oxygen species 
(mtROS) (76,77). As previously mentioned, it has been  shown that hypoxia and 
aldosterone can reproduce the effect of an inflammatory phenotype in adipose tissue, 
with loss of anticontractile property (71). The macrophage activation is responsible of 
both conditions because free radical scavengers are able to rescue the anticontractile 
function of adipose tissue (71). In conclusion, inflammation and oxidative stress are 
interrelated and associated with adipose tissue dysfunction  and they could contribute 
to arterial stiffness and hypertension (78,79), maybe through endothelial dysfunction 
(Figure 3). Macrophages in adipose tissue represent a key modulator of oxidative 
stress and systemic inflammation through the production of IL-6 and ROS (80). The 
important role of IL-6 and MCP-1 in the recruitment of inflammatory cells, in 
particular monocytes and macrophage,  and in the pathology of vascular disease 
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during obesity is described in a recent review (73). Decreased adiponectin level is 
involved in the process of macrophage infiltration (81) and is a consequence of 
inflammation and oxidative stress (80) (Figure 3). 
 
 
 
 
Figure 3: Hypothetical link between adipose tissue dysfunction, inflammation, oxidative stress and 
vascular disease. 
 
Therefore it’s clear that adiponectin is one of the key mediator of PVAT function 
which is altered in obesity. It was demonstrated that the effect of adiponectin on 
vascular tone is mediated by activation of potassium channel Calcium-dependent 
(BKCa channels) on vascular smooth muscle cells and adipocytes and by endothelial 
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mechanisms (82): adiponectin hyperpolarizes wild-type arteries, but not vessels from 
BKCa- knockout mice. Furthermore it seems that stimulated release of a 
hyperpolarizing factor (maybe adiponectin) from mesenteric artery PVAT induces 
electrical changes that involve myocyte BKCa channels (83).  Thereafter the 
intracellular downstream mechanisms which involve cGMP-dependent protein kinase 
(PKG) as a regulators of normal PVAT function was described. (84). Recently the 
involvement of BKCa channels in anticontractile function of perivascular adipose 
tissue was confirmed  (85). In particular, it has been shown that the anticontractile 
effect of PVAT completely disappeared after pre-incubation with iberiotoxin, a 
scorpion toxin that inhibits BKCa channels, in ob/ob mice, an animal model of 
obesity (B6. V-Lepob/OlaHsd) (85). In that study also the effects of melatonin, an 
endogenous hormone with antioxidant and vasculoprotective properties, on 
anticontractile properties of PVAT were addressed.  
 
5  The role of melatonin in vascular dysfunction 
Melatonin is an endogenous hormone that exerts antioxidant, antiinflammatory, 
antihyperlipidemic, and antihypertensive actions and it also modulates insulin 
secretion and action (86). 
It has been demonstrated that melatonin is able to improve mesenteric small resistance 
artery structure and endothelial function in spontaneously hypertensive rats (87). It 
has been shown that melatonin therapy is able to improve blood pressure, lipid 
profile, and parameters of oxidative stress in patients with metabolic syndrome (88). 
Furthermore, chronic administration of melatonin in rats fed a normal or high-fat diet, 
resulted in significant reduction in body weight, in circulating insulin, glucose and 
triglyceride mean levels and was able to modulate the normal circadian pattern of 
19 
 
plasma adiponectin (89). It has also been proposed that melatonin-induced 
hypertrophy and functional activation of brown adipose tissue may provide a potential 
target for treatment of obesity in humans (90). Therefore, in obesity melatonin might 
be able to reduce pro-inflammatory cytokines and to increase adiponectin level with 
consequent modulation of PVAT function. Recently, it has been demonstrated that 
prolonged administration of melatonin is able to reduce hyperglycemia associated 
with obesity in hyperphagic mouse and to ameliorate the inflammation in the 
perivascular environment (85). In particular ob/ob mice treated with melatonin 
showed a marked reduction in the expression of endothelin-1 (ET-1), interleukin-6 
(IL-6) , and metalloproteases 2 and 9; in addition we observed that the increased 
expression of both TNF-α and CD68 in visceral fat sections from ob/ob mice was 
significantly reduced after melatonin treatment. Anticontractile function of PVAT, 
partially lost in a model of animal obesity, may be restored by melatonin treatment 
but only in presence of an intact PVAT, indicating the importance of PVAT oxidative 
stress in vascular dysfunction observed in obese animals (85).   
Aging represents another vascular dysfunction condition which is associated with a 
progressively decrease of the nighttime peak of melatonin concentrations. During 
aging structural and functional changes have been observed. In particular, the effect of 
aging on vascular endothelium and small muscle cells (SMC) has been widely 
investigated, while less is known about the changes of PVAT. A senescence-
accelerated prone mouse (SAMP8), a model of  age-related vascular dysfunction with 
associated increase in blood pressure and cognitive decline has been recently 
investigated (91, 92). It has been demonstrated that  in SAMP8 mice there was an 
overexpression of endothelin 1 (ET-1), inducible nitric oxide synthase (iNOS) and 
cyclooxygenase 2 (COX-2), all markers of oxidative stress together with a reduced 
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level of endothelial nitric oxide synthase (eNOS) and cyclooxygenase 1 (COX-1) 
(93). In addition, in SAMP8 mice PVAT had lost its protective anti contractile effect. 
Also long term treatment with melatonin in SAMP8 was able to increase some 
vasculoprotective markers, to decrease oxidative stress and inflammation and to 
restore the anticontractile effect of perivascular adipose tissue (93). Decreased 
expression of adiponectin and adiponectin receptor 1 was also observed in visceral fat 
of untreated aging mice, whereas a significant increase was observed after melatonin 
treatment (93).  The increased production/activity of adiponectin might contribute to 
explain the improvement of the anticontractile action of perivascular fat observed in 
the mesenteric small resistance arteries of SAMP8 mice after chronic treatment with 
melatonin (93). 
 
6 Conclusions  
In conclusion, several evidences suggest a key role of PVAT as regulator of vascular 
tone through different mechanisms. It is clear that the RAS activity in adipose tissue 
plays an important role on PVAT function and the correction of the imbalance 
between the different RAS components is crucial for the maintenance of vascular 
tone. Besides the known antihypertensive effects of ACE-inhibitors and AT1R-
blockers and their effect on reduction of the incidence of new-onset diabetes (94-96), 
they are able to increase circulating levels of adiponectin. In particular, it has been 
demonstrated that the levels of myocardial adiponectin and its type 1 receptor are 
decreased in type 2 diabetic rats and that telmisartan treatment may correct these 
alterations (97). In addition melatonin represents a potential therapeutic biological 
target in clinical conditions such as obesity and for delaying physiological and 
pathological alteration related to early vascular aging.    
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Further studies are needed for fully understanding the potential implications of 
perivascular adipose tissue properties on vascular function in humans.   
22 
 
REFERENCES 
References Papers of particular interest, published recently, have been 
highlighted as: 
 • Of importance  
•• Of major importance 
 
(1)  Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol 
Cell Endocrinol. 2010 Mar 25;316(2):129-39. 
 
(2) •• Soltis EE., Cassis LA. Influence of adipose tissue on rat aortic smooth muscle 
responsiveness. Clinical & Experimental Hypertension – Part A . Theory & Practice 
1991; 13(2): 277-96. first demonstration that PVAT might be important for vascular 
regulation 
 
(3) Lohn M, Dubrovska G, Lauterbach B, Luft FC, Gollasch M. Sharma AM. 
Periadventitial fat releases a vascular relaxing factor. FASEB Journal 2002; 
16(9):1057-63.  
 
(4) Dubrovska G, Verlohren S, Luft FC, Gollasch M. Mechanisms of ADRF release 
from rat aortic adventitial adipose tissue. American Journal of Physiology – Heart & 
Circulatory Physiology 2003; 286(3): H1107-13. 
 
23 
 
(5) Gao YJ, Lu C, Su LY, Sharma AM, Lee RMKW. Modulation of vascular function 
by perivascular adipose tissue: the role of endothelium and hydrogen peroxide. 
[comment]. British Journal of Pharmacology 2007; 151(3): 323-31. 
 
(6) Gao Y-J, Zeng Z-H, Teoh K, Sharma AM, Abouzahr L, Cybulsky I, et al. 
Perivascular adipose tissue modulates vascular function in the human internal thoracic 
artery. Journal of Thoracic & Cardiovascular Surgery 2005; 130(4): 1130-6 
 
(7) Archer SL, Gragasin FS, Wu X, Wang S, McMurtry S, Kim DH, et al. 
Endothelium-derived hyperpolarizing factor in human internal mammary artery is 
11,12- epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle 
BK (Ca) channels. Circulation 2003; 107(5): 769-76. 
 
(8) Verlohren S, Dubrovska G, Tsang S-Y, EEssin K, Luft FC, Huang Y, et al. 
Visceral periadventitial adipose tissue regulates arterial tone of mesenteric arteries 
[comment]. Hypertension 2004; 44(3): 271-6. 
 
(9) Gálvez B, de Castro J, Herold D, Dubrovska G, Arribas S, González MC, 
Aranguez I, Luft FC, Ramos MP, Gollasch M, Fernández Alfonso MS. Perivascular 
adipose tissue and mesenteric vascular function in spontaneously hypertensive rats. 
Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1297-302.  
 
(10) Baker AR, Silva NF, Quinn DW, Harte AL, Pagano D, Bonser RS, Kumar S, 
McTernan PG. Human epicardial adipose tissue expresses a pathogenic profile of 
24 
 
adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol. 2006 
Jan 13;5:1. 
 
(11) Quehenberger P, Exner M, Sunder-Plassmann R, Ruzicka K, Bieglmayer C, 
Endler G, et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res. 
2002;90(6):711–8. 
 
(12) Korda M, Kubant R, Patton S, Malinski T. Leptin-induced endothelial 
dysfunction in obesity. Am J Physiol Heart Circ Physiol. 2008;295(4):H1514–21. 
 
 
(13) Ketonen J, Shi J, Martonen E, Mervaala E. Periadventitial adipose tissue 
promotes endothelial dysfunction via oxidative stress in diet-induced obese C57BI/6 
mice. Circ J. 2010;74(7):1479–87. 
 
(14) Yamamoto K, Kiyohara T, Murayama Y, Kihara S, Okamoto Y, Funahashi T, Ito 
T, Nezu R, Tsutsui S, Miyagawa JI, Tamura S, Matsuzawa Y, Shimomura I, 
Shinomura Y. Production of adiponectin, an anti-inflammatory protein, in mesenteric 
adipose tissue in Crohn's disease. Gut. 2005 Jun;54(6):789-96. 
 
(15) Trujillo ME, Scherer PE. Adiponectin—journey from an adipocyte secretory 
protein to biomarker of the metabolic syndrome. Journal of Internal Medicine 
2005;257(2):167-75. 
 
25 
 
(16) Chow W-S, Cheung BMY, Tso AWK, Xu A, Wat NMS, Fong CHY, et al. 
Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year 
prospective study. [comment]. Hypertension 2007; 49(6): 1455-61. 
 
(17) Li H-Y, Chiu Y-F, Hwu C-M, Sheu WH-H, Hung Y-J, Fujimoto W, et al. The 
negative correlation between plasma adiponectin and blodd pressure depends on 
obesity: a family-based association study in SAPPHIRe. [comment]. American 
Journal of Hypertension 2008; 21(4): 471-6. 
 
(18) • Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, et al. 
Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 
2004; 43(6): 1318-23. This is one of the firs study that describes the several protective 
properties of adiponectin against hypertension 
 
(19) YamauchiT, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, et al. Globular 
adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from 
atherosclerosis. Journal of Biological Chemistry 2003; 278(4): 2461-8. 
 
(20) YamauchiT, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-
derived hormone adiponectin reverses insulin resistance associated with both 
lipoatrophy and obesity. [comment]. Nature Medicine 2001; 7(8): 941-6. 
 
(21) Deng G, Long Y, Yu YR, Li MR (2010). Adiponectin directly improves 
endothelial dysfunction in obese rats through the AMPK-eNOS Pathway. Int J Obes 
(Lond) 2010, 34: 165–171 
26 
 
 
(22) Luo N, Liu J, Chung BH, Yang Q, Klein RL, Garvey WT, et al. Macrophage 
adiponectin expression improves insulin sensitivity and protects against inflammation 
and atherosclerosis. Diabetes. 2010;59(4):791–9. 
 
(23) Li FY, Cheng KK, Lam KS, Vanhoutte PM, Xu A. Cross-talk between adipose 
tissue and vasculature: role of adiponectin. Acta Physiol (Oxf). 2011;203(1):167–80 
 
(24) Cao Y, Tao L, Yuan YX, Jiao XY, Lau WB, Wang YJ, et al. Endothelial 
dysfunction in adiponectin deficiency and its mechanisms involved. J Mol Cell 
Cardiol. 2009;46(3):413–9. 
 
(25) Sowers JR. Endocrine functions of adipose tissue: focus on adiponectin. Clin 
Cornerstone 2008, 9: 32–38, discussion 39–40 
 
(26) Iacobellis G, Pistilli D, Gucciardo M, Leonetti F, Miraldi F, Brancaccio G, et al. 
Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients 
with coronary artery disease. Cytokine. 2005;29(6):251–5. 
 
(27) •• Greenstein AS, Khavandi K, Withers SB, Sonoyama K, Clancy O, Jeziorska 
M, Laing I, Yates AP, Pemberton PW, Malik RA, Heagerty AM. Local inflammation 
and hypoxia abolish the protective anticontractile properties of perivascular fat in 
obese patients. Circulation 2009; 119(12): 1661-70. This is the first demonstration of 
anticontractile effect of perivascular adipose tissue in obese patients 
 
27 
 
(28) An SJ, Boyd R, Wang Y, Qiu X, Wang HD. Endothelin-1 expression in vascular 
adventitial fibroblasts. Am J Physiol Heart Circ Physiol 2006;290: H700-H708 
 
(29) Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. 
Circ Res. 2005; 96: 939–949. 
 
(30) Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 
2005; 115: 1111–1119. 
 
(31) Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 
2006; 444: 881–887. 
 
(32) Lazar MA. How obesity causes diabetes: not a tall tale. Science. 2005; 307: 373–
375. 
 
(33) Lu C, Zhao AX, Gao YJ, Lee RM. Modulation of vein function by perivascular 
adipose tissue. Eur J Pharmacol. 2011 Apr 25;657(1-3):111-6. 
 
(34) Malinowski M, Deja MA, Gołba KS, Roleder T, Biernat J, Woś S. Perivascular 
tissue of internal thoracic artery releases potent nitric oxide and prostacyclin-
independent anticontractile factor. Eur J Cardiothorac Surg. 2008 Feb;33(2):225-31. 
 
(35) Lee RM, Ding L, Lu C, Su LY, Gao YJ. Alteration of perivascular adipose tissue 
function in angiotensin II-induced hypertension. Can J Physiol Pharmacol. 2009 
Nov;87(11):944-53 
28 
 
 
(36) Lee RMKW, Lu C, Su LY, Gao YJ. Endothelium-dependent relaxation factor 
released by perivascular adipose tissue. J Hypertens. 2009;27(4):782–90. 
 
(37) • Engeli S, Gorzelniak K, Kreutz R, Runkel N, Distler A, Sharma AM. Co-
expression of renin-angiotensin system genes in human adipose tissue. Journal of 
Hypertension 1999; 17: 555-560. The study describes the role of the renin-angiotensin 
system in human adipose tissue 
 
(38)   Gàlvez-Prieto B, Bolbrinker J, Stucchi P, de Las Heras AI, Merino B, Arribas S, 
Ruiz-Gayo M, Huber M, Wehland M, Kreutz R, Fernandez-Alfonso MS. 
Comparative expression analysis of the renin-angiotensin system components 
between white and brown perivascular adipose tissue. Journal of Endocrinology 
2008; 197: 55-64. 
 
(39) Goossens GH, Jocken JW, Blaak EE, Schiffers PM, Saris WH, van Baak MA. 
Endocrine role of the renin-angiotensin system in human adipose tissue and muscle: 
effect of beta-adrenergic stimulation. Hypertension 2007 Mar;49(3):542-7. 
 
(40) • Perivascular adipose tissue and local Renin-Angiotensin System. From Cassis 
LA, Police SB, Yiannikouris F, Thatcher SE. Local adipose tissue renin-angiotensin 
system. Curr Hypertens Rep 2008; 10(2): 93-98. This study is a review of the 
important role of adipose tissue renin-angiotensin system  
 
29 
 
41)  Campbell DJ, Habener JF. Cellular localization of AGT gene expression in brown 
adipose tissue and mesentery: quantification of messenger ribonucleic acid abundance 
using hybridization in situ. Endocrinology 1987; 121: 1616-1626 
 
(42) Cassis LA, Lynch KR, Peach MJ. Localization of angiotensinogen messenger 
RNA in rat aorta. Circulation Research 1988a; 62: 1259-1262 
 
(43) Shiling P, Mallow H, Trindl A, Loffler G. Evidence for a local renin angiotensin 
system in primary cultured human preadipocytes. Internal Journal Obes Relat Metab 
Disord. 1999; 23: 336-341. 
 
(44) Saye J, Linch KR, Peach MJ. Changes in angiotensinogen messenger RNA in 
differentiating 3T3- F442A adipocytes. Hypertension 1990; 15: 867-871 
 
(45) Hainault I, Nebout G, Ardouin BB, Quignard-Boulangé A. Developmental 
changes in AGT expression and its secretion in the Zucker rat: adipose tissue-specific 
effect of FA genotype. Int J Obes Relat Metab Disord. 1998; 22(suppl 3): S103 
Abstract. 
 
(46) Giacchetti G, Faloia E, Sardu C, Mariniello B, Garrapa GGM, Gatti C, Camilloni 
MA, Mantero F. Different gene expression of the RAS in human subcutaneous and 
visceral adipose tissue. Int J Obes Relat Metab Disord. 1999;23(suppl 5): S71. 
Abstract. 
 
30 
 
(47) Phillips MI, Speakman EA, Kimura B. Levels of angiotensin and molecular 
biology of the tissue renin angiotensin systems. Regulatory Peptides 1993; 43: 1-20. 
 
(48) Shenoy U, Cassis L. Characterization of renin activity in brown adipose tissue. 
Am J Physiol. 1997; 272: C989- C999. 
 
(49) Kupiers,I., van der Harst, P., Navis, G., et al. Nuclear hormone receptors as 
regulators of the renin-angiotensin-aldosterone system. Hypertension 2008; 51: 1442-
1448. 
 
(50) Archard V, Boullu-Ciocca S, Desbriere R, Nguyen G, Grino M. Renin receptor 
expression in human adipose tissue. American Journal of Physiology, Regulatory, 
Integrative and Comparative Physiology 2007; 292: 274-282. 
 
(51) Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the 
physiological and pathophysiological actions of angiotensin II in vascular smooth 
muscle cells. Pharmacol Rev 2000; 52: 639-672 
 
(52) Schling P, Mallow H, Trindl A, Löffler G. Evidence for a local renin angiotensin 
system in primary cultured human preadipocytes.. Int J Obes Relat Metab Disord. 
1999 Apr;23(4):336-41. 
 
(53) Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade 
prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40: 609-611. 
 
31 
 
(54) Matsushita K, Wu Y, Okamoto Y, Pratt RE, Dzau VJ. Local renin-angiotensin 
expression regulates Human mesenchymal stem cell differentiation to adipocytes. 
Hypertension 2006; 48: 1095-1102. 
 
(55) Jones BH, Standridge MK, Moustaid N. Angiotensin II increases lipogenesis in 
3T3-L1 and human adipose cells. Endocrinology 1997; 138(4): 1512-1519. 
 
(56) Furuhashi M, Ura N, Higashiura K, et al. Blockade of the renin–angiotensin 
system increases adiponectin concentrations in patients with essential hypertension. 
Hypertension. 2003;42:76–81 
  
(57) Lee MH, Song HK, Ko GJ, et al. Angiotensin receptor blockers improve insulin 
resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int. 
2008;74:890–900 
 
(58) Rinaldi B, Di Filippo C, Capuano A, Donniacuo M, Sodano L, Ferraraccio F, 
Rossi F, D'Amico M. Adiponectin elevation by telmisartan ameliorates ischaemic 
myocardium in Zucker diabetic fatty rats with metabolic syndrome. Diabetes Obes 
Metab. 2012 Apr;14(4):320-8. 
 
(59)  Nakamura T, Kawachi K, Saito Y, Saito T, Morishita K, Hoshino J, Hosoi T, 
Iwasaki T, Ohyama Y, Kurabayashi M. Effects of ARB or ACE-inhibitor 
administration on plasma levels of aldosterone and adiponectin in hypertension. Int 
Heart J. 2009;50:501–512. 
 
32 
 
(60) Ran J, Hirano T, Fukui T, Saito K, Kageyama H, Okada K, Adachi M. 
Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in 
rats: an implication for hypertension-related insulin resistance. Metabolism. 
2006;55:478–488. 
 
(61) Guo B, Li Y, Han R, Zhou H, Wang M. Angiotensin II upregulation of 
cardiomyocyte adiponectin production is nitric oxide/cyclic GMP dependent. Am J 
Med Sci. 2011 May;341(5):350-5. 
 
(62) Onat A. Metabolic syndrome: nature, therapeutic solutions and options. Expert 
Opin Pharmacother. 2011 Aug;12(12):1887-1900. 
 
(63) Okada S, Kozuka C, Masuzaki H, Yasue S, Ishii-Yonemoto T, Tanaka T, 
Yamamoto Y, Noguchi M, Kusakabe T, Tomita T, Fujikura J, Ebihara K, Hosoda K, 
Sakaue H, Kobori H, Ham M, Lee YS, Kim JB, Saito Y, Nakao K. Adipose tissue-
specific dysregulation of angiotensinogen by oxidative stress in obesity. Metabolism 
Journal 2010; 59(9): 1241-1251. 
 
(64) Farquharson CA, Struthers AD. Aldosterone induces acute endothelial 
dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. 
Clin Sci (Lond) 2002; 103(4): 425-431. 
 
(65) Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced 
inflammation in the rat heart: role of oxidative stress. The American Journal of 
Pathology 2002; 161(5): 1773-1781. 
33 
 
 
(66) Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T, Kihara S, Funahashi 
T, Shimomura I. Blockade of mineralcorticoid receptor reverses adipocyte 
dysfunction and insulin resistance in obese mice. Cardiovascular Research 2009. 
 
(67) Flynn C, Bakris GL. Interaction between Adiponectin and Aldosterone. 
Cardiorenal Med. 2011;1(2):96-101. 
 
(68) Lemarié CA, Paradis P, Schiffrin EL. New insights on signaling cascades 
induced by cross-talk between angiotensin II and aldosterone. J Mol Med 2008; 86(6): 
673-678. 
 
 
(69) Lu C, Su LY, Lee RM, Gao YJ. Mechanisms for perivascular adipose tissue-
mediated potentiation of vascular contraction to perivascular neuronal stimulation: the 
role of adipocyte-derived angiotensin II. Eur J Pharmacol. 2010 May 25;634(1-
3):107-12. 
 
(70) Lu C, Su LY, Lee RM, Gao YJ. Alterations in perivascular adipose tissue 
structure and function in hypertension. Eur J Pharmacol. 2011 Apr 10;656(1-3):68-
73. 
 
(71) •• Withers SB, Agabiti Rosei C, Livingstone DM, Little MC, Aslam R, Malik 
RA, Heagerty AM. Macrophage activation is responsible for loss of anticontractile 
function in inflamed perivascular fat. Artherioscler Thromb, Vascular, Biol 2011 
34 
 
Apr;31(4):908-13. This study demonstrates the involvement of macrophage activation 
in loss of anticontractile function of perivascular adipose tissue 
 
(72) • Rosei CA, Withers SB, Belcaid L, De Ciuceis C, Rizzoni D, Heagerty AM. 
Blockade of the renin-angiotensin system in small arteries and anticontractile function 
of perivascular adipose tissue. J Hypertens. 2015 May;33(5):1039-45. doi: 
10.1097/HJH. This is the first demonstration of restore anticontractile effect of 
perivascular fat with blockade of the renin-angiotensin system in small arteries 
 
(73) • Huang Cao ZF1, Stoffel E, Cohen P. Role of perivascular adipose tissue in 
vascular physiology and pathology. Hypertension 2017; 69:770-777. This is a recent 
overview of the role of perivascular adipose tissue in vascular structure and reactivity 
 
(74) Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, et al. 
Reduction of macrophage infiltration and chemoattractant gene expression changes in 
white adipose tissue of morbidly obese subjects after surgery-induced weight loss. 
Diabetes 2005; 54(8): 2277-86. 
 
(75) Chen B, Lam KSL, Wang Y, Wu D, Larn MC, Shen J, et al. Hypoxia 
dysregulates the production of adiponectin and plasminogen activator inhibitor-1 
indipendent of reactive oxygenspecies in adipocytes. Biochemical e Biophysical 
Research Communications 2006; 341 (2): 549-56. 
 
35 
 
(76) Patten DA, Lafleur VN, Robitaille GA, Chan DA, Giaccia AJ, Richard DE. 
Hypoxia-inducible factor-1 activation in nonhypoxic conditions: the essential role of 
mitochondrial-derived reactive oxygen species. Mol Biol Cell 2010; 21(18): 3247-57. 
 
(77) Elisabeth L. Pagé, Geneviéve A Robitaille, Pouysségur J, Richard DE. Induction 
of hypoxia-inducible factor-1α by transcriptional and translational mechanisms. J Biol 
Chem 2002; 277(50): 48403-9. 
 
(78) • Schnabel R, Larson MG, Dupuis J, Lunetta KL, Lipinska I, Meigs JB, Yin X, 
Rong J, Vita JA, Newton-Cheh C, Levy D, Keaney JF Jr, Vasan RS, Mitchell GF, 
Benjamin EJ. Relations of inflammatory biomarkers and common genetic variants 
with arterial stiffness and wave reflection. Hypertension. 2008 Jun;51(6):1651-7.  
SourceNational Heart Lung and Blood Institute Framingham Study, Framingham, 
Mass., USA. This study shows that inflammation and oxidative stress are interrelated 
and associated with adipose tissue dysfunction  and they could contribute to arterial 
stiffness and hypertension  
 
(79) Chae CU, Lee RT, Rifai N, Ridker PM. Blood pressure and inflammation in 
apparently healthy men. Hypertension. 2001 Sep;38(3):399-403. 
 
(80) Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, 
Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in 
obesity and its impact on metabolic syndrome. J Clin Invest. 2004 Dec;114(12):1752-
61. 
 
36 
 
(81) Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, 
Utsunomiya K, Nagai R. Direct reciprocal effects of resistin and adiponectin on 
vascular endothelial cells: a new insight into adipocytokine-endothelial cell 
interactions. Biochem Biophys Res Commun. 2004 Feb 6;314(2):415-9. 
 
(82) • Lynch FM1, Withers SB, Yao Z, Werner ME, Edwards G, Weston AH, 
Heagerty AM. Perivascular adipose tissue-derived adiponectin activates BK(Ca) 
channels to induce anticontractile responses. Am J Physiol Heart Circ Physiol. 2013 
Mar 15;304(6):H786-95. This study is the first demonstration that the mechanism 
underlies the anticontractile effect of perivascular adipose tissue involves the 
activation of BK(Ca) channels 
 
(83) Weston AH, Egner I, Dong Y, Porter EL, Heagerty AM, Edwards G. Stimulated 
release of a hyperpolarizing factor (ADHF) from mesenteric artery perivascular 
adipose tissue: involvement of myocyte BKCa channels and adiponectin. Br J 
Pharmacol. 2013 Aug;169(7):1500-9 
 
(84) • Withers SB, Simpson L, Fattah S, Werner ME, Heagerty AM. cGMP-
dependent protein kinase (PKG) mediates the anticontractile capacity of perivascular 
adipose tissue. Cardiovasc Res. 2014 Jan 1;101(1):130-7. This study shows the role of 
cGMP-dependent protein kinase (PKG) as a principal mediators of perivascular 
adipose tissue activity 
 
(85) Agabiti-Rosei C, De Ciuceis C, Rossini C, Porteri E, Rodella LF, Withers SB, 
Heagerty AM, Favero G, Agabiti-Rosei E, Rizzoni D, Rezzani R. Anticontractile 
37 
 
activity of perivascular fat in obese mice and the effect of long-term treatment with 
melatonin. J. Hypertens. 2014 Jun;32(6):1264-74 
 
(86) Bonnefont-Rousselot D1, Collin F, Jore D, Gardès-Albert M. Reaction 
mechanism of melatonin oxidation by reactive oxygen species in vitro. J Pineal Res. 
2011 Apr;50(3):328-35. 
 
(87) Rezzani R, Porteri E, De Ciuceis C, Bonomini F, Rodella LF, Paiardi S, Boari 
GE, Platto C, Pilu A, Avanzi D, Rizzoni D, Agabiti Rosei E. Effects of melatonin and 
Pycnogenol on small artery structure and function in spontaneously hypertensive rats. 
Hypertension. 2010 Jun;55(6):1373-80. 
 
(88) Koziróg M1, Poliwczak AR, Duchnowicz P, Koter-Michalak M, Sikora J, 
Broncel M. Melatonin treatment improves blood pressure, lipid profile, and 
parameters of oxidative stress in patients with metabolic syndrome. J Pineal Res. 
2011 Apr;50(3):261-6 
 
(89) Ríos-Lugo MJ1, Cano P, Jiménez-Ortega V, Fernández-Mateos MP, Scacchi PA, 
Cardinali DP, Esquifino AI. Melatonin effect on plasma adiponectin, leptin, insulin, 
glucose, triglycerides and cholesterol in normal and high fat-fed rats. J Pineal Res. 
2010 Nov;49(4):342-8. 
 
(90) • Tan DX, Manchester LC, Fuentes-Broto L, Paredes SD, Reiter RJ. Significance 
and application of melatonin in the regulation of brown adipose tissue metabolism: 
relation to human obesity. Obes Rev. 2011 Mar;12(3):167-88. This study describes 
38 
 
melatonin function in brown adipose tissue metabolism suggesting a potential target 
for treatment of obesity in humans 
 
(91) Takeda T. Senescence-accelerated mouse (SAM): a biogerontological resource in 
aging research. Neurobiol Aging. 1999 Mar-Apr;20(2):105-10. 
 
(92) Butterfield DA, Poon HF. The senescence-accelerated prone mouse (SAMP8): a 
model of age-related cognitive decline with relevance to alterations of the gene 
expression and protein abnormalities in Alzheimer's disease. Exp Gerontol. 2005 
Oct;40(10):774-83. 
 
(93) Agabiti-Rosei C, Favero G, De Ciuceis C, Rossini C, Porteri E, Rodella LF, 
Franceschetti L, Maria Sarkar A, Agabiti-Rosei E, Rizzoni D, Rezzani R. Effect of 
long-term treatment with melatonin on vascular markers of oxidative 
stress/inflammation and on the anticontractile activity of perivascular fat in aging 
mice. Hypertens Res. 2017 Jan;40(1):41-50. 
 
(94) Narkiewicz K. Diagnosis and management of hypertension in obesity. Obes Rev. 
2006 May;7(2):155-62. 
 
(95) Kotchen TA. Obesity-related hypertension: epidemiology, pathophysiology, and 
clinical management. Am J Hypertens. 2010 Nov;23(11):1170-8. 
 
(96) Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, 
Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, et al. 2007 
39 
 
Guidelines for the management of arterial hypertension: The Task Force for the 
Management of Arterial Hypertension of the European Society of Hypertension 
(ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007 
Jun;28(12):1462-536. 
 
(97) Guo Z, Zheng C, Qin Z, Wei P. Effect of telmisartan on the expression of cardiac 
adiponectin and its receptor 1 in type 2 diabetic rats. J Pharm Pharmacol. 2011 
Jan;63(1):87-94.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
